AZTA — Azenta, Inc.

Summary of Azenta's Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $145 million, up 1% year-over-year; down 3% organically.
• Adjusted EBITDA Margin: 5.4%, a decline of 320 basis points year-over-year.
• Non-GAAP EPS: Loss of $0.04 per share.
• Free Cash Flow: $5 million, supported by improved working capital.
• Cash Position: $565 million in cash, cash equivalents, and marketable securities; no debt outstanding.
• Goodwill Impairment: $112.4 million for Multiomics and $36.6 million for Sample Management Solutions due to reduced fair value estimates.

2. Strategic Updates and Business Highlights

• Multiomics: Continued growth in Europe and Asia, but North America faced lower volumes due to competitive pressures and execution challenges.
• Sample Management Solutions: Strong performance in biorepository solutions, but overall revenue impacted by reduced demand for capital-intensive products.
• Operational Improvements: Enhanced on-time delivery in consumables and instruments from 15% to 70%. Significant reductions in turnaround times for RNA-Seq offerings.
• Leadership Changes: Appointment of Trey Martin as President of the Multiomics business to drive transformation and improve execution.
• Acquisition of UK Biocentre: Integration is progressing well, enhancing Azenta's presence in the European life sciences market.

3. Forward Guidance and Outlook

• Revised Full-Year Guidance:
  • Total revenue expected between $603 million to $621 million (including UKBC).
  • Organic revenue projected to decline 2% to grow 1% (previously 3% to 5% growth).
  • Adjusted EBITDA margin expected to decline approximately 125 basis points to flat year-over-year.
• Segment Expectations:
  • Sample Management Solutions: Low single-digit organic growth.
  • Multiomics: Mid-single-digit decline.
• Second Half Expectations: Anticipated low single-digit organic revenue growth in Q3, followed by a low single-digit decline in Q4.

4. Bad News, Challenges, or Points of Concern

• Execution Shortfalls: Internal execution issues have led to lower volumes and reduced fixed cost absorption, particularly in North America.
• Competitive Pressures: Increased competition in the Multiomics segment, especially in gene synthesis, has impacted performance.
• Quality Issues: Ongoing remediation of automated storage systems has delayed recovery and incurred additional costs.
• Market Environment: Cautious customer spending and constrained research funding, particularly in North America, are affecting demand.

5. Notable Q&A Insights

• Cadence of Performance: Q2 saw initial improvements in bookings, but a typical seasonal spike did not materialize, leading to order delays.
• Human Capital Issues: The company is addressing gaps in its sales force, particularly in North America, and plans to enhance productivity through new hires and leadership.
• Long-Range Plan (LRP) Reset: The LRP timeline has been pushed back by one year to 2029, but the same financial targets remain, reflecting confidence in market opportunities.
• B Medical Systems Update: The transaction remains pending due to financing issues, with no immediate resolution timeline provided.

Overall, while Azenta is experiencing challenges in execution and market conditions, it remains committed to its strategic initiatives and operational improvements to drive future growth.